Servier and X-Chem, a privately held drug discovery company, announced a partnership to identify and develop novel small molecules for the treatment of neurological disorders.
X-Chem will utilize its DNA-Encoded library platform to identify novel small molecule leads directed towards Central Nervous System (CNS) targets of interest to Servier.
“Our partnership with X-Chem supports Servier’s drive for innovative drug discovery approaches towards new treatments for the benefit of patients suffering from neurological diseases. Combining our expertise gives us a truly valuable opportunity to advance this expanding internal program of drug discovery projects here at Servier, with the ultimate goal of bringing forward new and effective treatments to slow the progression of these devastating diseases.”Ross Jeggo, Head of the Neurology & Immuno-Inflammation therapeutic area at Servier
In the field of neurology, Servier focuses its research on neurodegenerative diseases. Servier targets proteinopathies, characterized by abnormal accumulation of certain proteins, such as Parkinson’s disease or rare diseases such as amyotrop.